Welcome to Idenix Pharmaceuticals
  • contact us
  • search
  • site map

Idenix Home

  • About Idenix
    • Overview
    • Executive Management
    • Board of Directors
    • Corporate Compliance & Governance
    • Careers
    • Locations
  • Antiviral Focus
    • About the Diseases
    • Idenix Antiviral Pipeline
    • Publications & Presentations
    • Clinical Trials
  • HCV
    • Innovation
    • Drug Discovery & Development
    • HCV Pipeline
    • Evolution of Treatment
    • Publications
    • Clinical Trials
  • Corporate Partners
    • Novartis Pharma AG
    • Business Development
  • Patient Support
    • Disease Information
    • Clinical Trials
    • Contact Idenix
  • Investor
    • Stock Information
    • Financial Highlights
    • SEC Filings
    • Corporate Compliance and Governance
    • News Releases
    • Media Kit
    • Events
    • Investor Presentations
    • Investor FAQ
    • Product Pipeline
    • Requests & Contacts

View Our Latest HCV Publications and Presentations

Follow @IdenixPharma

Stock Quote
IDIX
Stock Quote Investor information

January 9, 2012
IDENIX REPORTS POSITIVE INTERIM DATA FOR HCV NUCLEOTIDE INHIBITOR, IDX184
Read more

January 9, 2012
IDENIX REPORTS ADVANCEMENT OF HCV DEVELOPMENT PIPELINE
Read more

 
terms of use      privacy policy